News Search Results
Dec 25, 2025, 22:03 ET Science and Technology Daily Releases 2025 Top Sci-tech News
This discovery clarifies the totipotency mechanism in plant cells and offers new possibilities for genetic improvement of crops and agricultural biotechnology.8. China's Scientists First to Prepare Large-area Two-dimensional Metal MaterialsScientists from the Institute of Physics, Chinese
More news about: Science and Technology Daily
Dec 24, 2025, 05:11 ET Architects of Progress: Celebrating India's Most Influential Knowledge Leaders
emerging as one of India's most dynamic biotechnology and green innovation enterprises, redefining the intersection of science, sustainability, and entrepreneurship. Formerly known as JE JE Enterprises Private Limited, the organisation operates across algae biotechnology, nutraceuticals, controlled-environment
More news about: Kiteskraft Productions LLP
Dec 23, 2025, 20:20 ET Nona Biosciences Expands Integrated Discovery-to-Clinical Capabilities Through Strategic Platform Growth
CAMBRIDGE, Mass., Dec. 23, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the expansion of its integrated discovery and
More news about: Nona Biosciences
Dec 23, 2025, 07:00 ET The TANAKA Growth Fund Achieves #1 Lipper Ranking for 5-Year Performance Through November 2025
with 12 holdings up more than 30% year-to-date and three positions more than tripling, driven by contributions from multiple sectors including biotechnology, critical minerals, clean energy, consumer staples, mining, technology, and semiconductors. We remain focused on sourcing and researching new opportunities
More news about: Tanaka Capital Management
Dec 22, 2025, 12:00 ET BioFlorida Announces Appointment of Dr. Anthony Japour, CEO of iTolerance, Inc., as Chair of the Southeast Chapter
foster connections and support continued growth in the Southeast Florida life sciences community."Anthony brings deep experience across biotechnology and large pharmaceutical organizations, along with a strong understanding of what it takes to build and scale innovation," said Mark Glickman, president
More news about: BioFlorida
Dec 22, 2025, 10:15 ET Single-molecule Real-time (SMRT) Sequencing worth $5.32 billion by 2030| MarketsandMarkets™
others.Browse Adjacent Markets: Biotechnology Market Research Reports & ConsultingRelated Reports:
More news about: MarketsandMarkets
Dec 22, 2025, 10:01 ET Next-generation Sequencing Services Market worth $8.77 billion by 2030 | MarketsandMarkets™
others.Browse Adjacent Markets: Biotechnology Market Research Reports & ConsultingRelated Reports:
More news about: MarketsandMarkets
Dec 22, 2025, 09:17 ET NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today reported completion of the safety analysis from its proof-of-concept
More news about: NeuroSense
Dec 22, 2025, 08:36 ET Origin Agritech Holds Annual R&D and Operations Management Conference, Establishes 2026 Strategic Priorities
approach to R&D innovation and commercial execution positions Origin to capitalize on the significant growth opportunities in China's agricultural biotechnology sector."The Company introduced its new core values framework, creatively expressed through the ORIGIN acronym:O:
More news about: Origin Agritech Limited
Dec 22, 2025, 08:31 ET MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement
CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that on December 19, 2025, it received formal notice from The Nasdaq Stock
More news about: MetaVia Inc.
Dec 22, 2025, 08:00 ET Beyond Celiac Investments Announces Funding of RheumaGen to Accelerate Treatments Towards a Cure in Celiac Disease
https://www.beyondceliac.org/beyond-celiac-investments/.About RheumaGen, Inc.:RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure common autoimmune diseases. RheumaGen focuses on editing the human leukocyte antigen (HLA),
More news about: Beyond Celiac
Dec 22, 2025, 08:00 ET RheumaGen Announces Funding Agreement with Beyond Celiac Investments to Accelerate Treatments Towards a Cure in Celiac Disease
and ultimately help deliver the first treatments and a cure for celiac disease.About RheumaGen, Inc.RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure common autoimmune diseases. RheumaGen focuses on editing the human leukocyte antigen (HLA),
More news about: RheumaGen, Inc.
Dec 22, 2025, 08:00 ET Flagship Pioneering and Repertoire® Immune Medicines Announce Agreement to Identify T Cell-Targeted Immune Medicines for Prostate Cancer Under Strategic Partnership with Pfizer
Sana Biotechnology,
More news about: Flagship Pioneering
Dec 22, 2025, 05:07 ET AusperBio Completes Patient Enrollment in Phase III AUSHINE Study of AHB-137 for Chronic Hepatitis B
2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company developing targeted oligonucleotide therapies for functional cure of chronic hepatitis B (CHB), today announced the completion of patient
More news about: AusperBio Therapeutics Inc.
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH® CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
based in Bologna, Italy, and Huntingdon Valley, Pa., U.S., is a wholly owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology, and diagnostics company headquartered in Florence, Italy, with more than 17,000 employees in 140 countries.[1]
More news about: Menarini Silicon Biosystems
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH® CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
based in Bologna, Italy, and Huntingdon Valley, Pa., U.S., is a wholly owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology, and diagnostics company headquartered in Florence, Italy, with more than 17,000 employees in 140 countries.[1]
More news about: Menarini Silicon Biosystems
Dec 22, 2025, 02:08 ET Mondego Bio Announces Selection of a PTPN2 Inhibitor Clinical Candidate and Targets First-in-Human Trials in H1 2026
CANTANHEDE, Portugal, Dec. 22, 2025 /PRNewswire/ -- Mondego Bio, a clinical-stage biotechnology company developing next-generation small-molecule immuno-oncology therapies, today announced the formal selection of its lead clinical candidate,
More news about: Mondego Bio
Dec 21, 2025, 07:20 ET T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma
feasibility and potential of the company's platform.About T-MAXIMUM PharmaceuticalT-MAXIMUM Pharmaceutical is an innovative biotechnology company dedicated to the development of allogeneic, off-the-shelf cell therapies, with a mission to address diseases for which there are currently
More news about: T-MAXIMUM PHARMACEUTICAL
Dec 19, 2025, 16:26 ET New York State's 2025 Emerging Technology Advisory Board Releases Final Report to Boost Biotech Innovation, Commercialization and Public Health Impact
(AI), the 2025 Board turned the State's attention to the next frontier: biotechnology.This year's ETAB brought together leaders from New York's business, non-profit and research institutions to focus on the broader biotechnology landscape, encompassing closely related sectors such as biopharmaceuticals
More news about: The Michael J. Fox Foundation for Parkinson's Research
Dec 19, 2025, 16:05 ET INOVIO Reports Inducement Grant Under Inducement Plan
PLYMOUTH MEETING, Pa., Dec. 19, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Dec 19, 2025, 14:23 ET AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Dec 19, 2025, 08:43 ET Mercury Bio and Meta-Flux Announce Strategic Collaboration to Advance Large-Molecule Therapeutics for Parkinson's and Alzheimer's Diseases
Mercury Bio, a biotechnology company advancing large-molecule therapeutics for neurodegenerative disease, and
More news about: Mercury Bio Inc. & Meta-Flux
Dec 19, 2025, 08:30 ET Xtalks Life Science Podcast Wraps Up 2025 with Deep Dives into Drug Development, Regulation, Clinical Trials and Innovation, Sets Sights on a Transformative 2026 by Xtalks
Throughout 2025, the podcast featured executives, scientists and industry experts from across pharmaceutical, biotechnology, medical device and healthcare organizations. Episodes explored topics ranging from drug development strategy and clinical trial innovation to regulatory
More news about: Xtalks
Dec 19, 2025, 07:45 ET BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
LINK.About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Dec 19, 2025, 06:59 ET Probiotic Yeast Market worth $16.23 billion by 2030- Exclusive Report by MarketsandMarkets™
a whole has become an efficient and competent producing medium for probiotic yeast, driven largely by cheap fermentation facilities, a skilled biotechnology workforce, and easy access to the main markets, allowing many firms to scale up production to serve both regional and export markets.The
More news about: MarketsandMarkets